At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 46 enrolled

Drug / intervention

Dasatinibdrug

Likely dose

Dasatinib 50mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00978731

NCT00978731Phase 1Completed

Compare CT.gov

Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Subjects Who Experienced Clinical Benefit on Protocol CA180-002

Bristol-Myers Squibb·interventional·Posted Sep 17, 2009·Updated Apr 28, 2011

In Brief

A Phase 1 clinical trial evaluating Dasatinib for Leukemia. Completed, enrolled 46 participants.

Detailed Summary

To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLeukemia

Countries--

Collaborators--

Timeline

Phase 1CompletedFinished

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartDec 2005

Primary CompletionSep 2008

First PostedSep 2009

TodayJul 2026

First PostedSep 17, 2009

Enrollment StartDec 1, 2005

Primary CompletionSep 1, 2008

TodayJul 2, 2026

Enrollment to primary: 2.8 yearsPosted 16.8 years ago

Interventions

Dasatinibdrug

Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules: * 5 days on, 2 days off * 6 days on, 1 day off * Continuous daily dosing Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study